[99mTc]Tc-Mebrofenin Hepatobiliary Scintigraphy SPECT/CT in the Quantitative Assessment of the Future Liver Remnant Function
June 2, 2023
Last Updated Month/Year
August 29, 2023
Country of Publication
The aim of this joint EANM/SNMMI/IHPBA procedure guideline is to provide general information and specific recommendations and considerations on the use of [99mTc]Tc-mebrofenin hepatobiliary scintigraphy (HBS) in the quantitative assessment and risk analysis before surgical intervention,
selective internal radiation therapy (SIRT) or before and after liver regenerative procedures. Although the gold standard to estimate future liver remnant (FLR) function remains volumetry, the increasing interest in HBS and the continuous request for implementation in major liver centers worldwide, demands standardization.
Male, Female, Adolescent, Adult, Child, Older adult
Health Care Settings
Ambulatory, Outpatient, Radiology services
Nurse, nurse practitioner, physician, physician assistant
Assessment and screening, Management
selective internal radiation therapy, SIRT
Arntz PJW, Deroose CM, Marcus C, Sturesson C, Panaro F, Erdmann J, Manevska N, Moadel R, de Geus-Oei LF, Bennink RJ. Joint EANM/SNMMI/IHPBA procedure guideline for [99mTc]Tc-mebrofenin hepatobiliary scintigraphy SPECT/CT in the quantitative assessment of the future liver remnant function. HPB (Oxford). 2023 Jun 2:S1365-182X(23)00546-4. doi: 10.1016/j.hpb.2023.06.001. Epub ahead of print. PMID: 37394397.